DETOUR System
Endologix, LLC · Decision date Oct 16, 2026
What did the FDA decide?
The FDA record for P220021/S009, titled "DETOUR System" with the decision code OK30 and dated 2026-10-16, lists this action as a 30-Day Notice under the supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The reported statement describes approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components. The record does not explain what those criteria are, what the prior criteria specified, or how the subassembly is manufactured, so those details remain absent from the supplied fields.
The P220021 identifier alone establishes the parent PMA relationship; it does not show that the full DETOUR System was newly approved. The product code QWM, the superficial femoral artery stent graft category, and the applicant Endologix, LLC, appear in the supplied fields. The stated purpose concerns visual acceptance criteria, not proof of safety or clinical effectiveness, and none of the supplied fields report trial data or clinical outcomes.
FDA approval order statement
approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220021/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Endologix, LLC
- Product code
- QWM
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent graft, bypass, superficial femoral artery.
- Applicant
- Endologix, LLC
- Product code
- QWM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220021 · Original PMA
DETOUR System
P220021/S009 received
Application receipt date recorded by FDA.
P220021/S009 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P220021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DETOUR SystemP220021 | Endologix, LLC | PMA approval | Jun 7, 2023 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endologix, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3910 Brickway Blvd., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220021/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records